Health AI Central
Peer-Reviewed Publication
Eur Radiol2026;36(10):7864-7873.October 1, 2026Journal Article

Clinical significance of lesion conspicuity on contrast-enhanced mammography.

Tali Amir1, Carol H Lee2, Molly P Hogan2, Sarah Eskreis-Winkler2, Varadan Sevilimedu3, Daniel J Long4, Noam Nissan5, Victoria L Mango2, Kimberly N Feigin2, Maxine S Jochelson6, Christopher E Comstock7, Janice S Sung8
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. amirt@mskcc.org.
2Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
3Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
4Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
5Department of Radiology, Sheba Medical Center, Tel Hashomer, Israel.
6Breastlink Women's Imaging; RADNET Beverly Hills, Los Angeles, CA, USA.
7Department of Radiology, New York-Presbyterian/Weill Cornell Medical Center, New York, NY, USA.
8Department of Radiology, Columbia University, New York, NY, USA.
PubMed DOI

Abstract

OBJECTIVE: To determine if lesion conspicuity on contrast-enhanced mammography (CEM) is independently associated with malignancy. MATERIALS AND METHODS: This retrospective, single-institution study identified consecutive abnormal screening and diagnostic CEMs between January 2019 and December 2021. The conspicuity of enhancing lesions on CEM recombined images was graded (low, moderate, or high) b…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.